[go: up one dir, main page]

AR121167A1 - DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR - Google Patents

DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Info

Publication number
AR121167A1
AR121167A1 ARP200101744A ARP200101744A AR121167A1 AR 121167 A1 AR121167 A1 AR 121167A1 AR P200101744 A ARP200101744 A AR P200101744A AR P200101744 A ARP200101744 A AR P200101744A AR 121167 A1 AR121167 A1 AR 121167A1
Authority
AR
Argentina
Prior art keywords
pyrrolo
isoindolin
thiazol
imidazol
acetamide
Prior art date
Application number
ARP200101744A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Roger David Norcross
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR121167A1 publication Critical patent/AR121167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Compuestos derivados de pirrolo[1,2-c]imidazol con actividad inhibitoria alostérica de EGFR, composición farmacéutica que los comprende y su uso en el tratamiento del cáncer de pulmón de células pequeñas. Reivindicación 1: Un compuesto seleccionado de 2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-2-[6-[4-(1-etil-4-piperidil)fenil]-1-oxo-4-(trifluorometil)isoindolin-2-il]-N-tiazol-2-il-acetamida; 2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-2-[6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxo-4-(trifluorometil)isoindolin-2-il]-N-tiazol-2-il-acetamida; 2-[4-(difluorometil)-6-[4-(1-etil-4-piperidil)fenil]-1-oxo-isoindolin-2-il]-2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-N-tiazol-2-il-acetamida; 2-[4-(difluorometil)-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxo-isoindolin-2-il]-2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-N-tiazol-2-il-acetamida; 2-[6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxo-4-(trifluorometil)isoindolin-2-il]-2-[rac-(6R)-6-fluoro-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamida; 2-[4-(difluorometil)-6-[4-(1-etil-4-piperidil)fenil]-1-oxo-isoindolin-2-il]-2-[rac-(6R)-6-fluoro-6,7-dihidro-5Hpirrolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamida; 2-[4-(difluorometil)-1-oxo-6-[4-[rac-(3R,4R)-1-etil-3-fluoro-4-piperidil]fenil]isoindolin-2-il]-2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-N-tiazol-2-il-acetamida; 2-[6-[2-[4-[(6-hidroxi-2-azaspiro[3.3]heptan-2-il)metil]fenil]etinil]-1-oxo-4-(trifluorometil)isoindolin-2-il]-2-[rac-(6R)-6-fluoro-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamida; 2-[4-(difluorometil)-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxo-isoindolin-2-il]-2-[rac-(6R)-6-fluoro-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamida; 2-[6-[2-[4-[(4-hidroxiazepan-1-il)metil]fenil]etinil]-1-oxo-4-(trifluorometil)isoindolin-2-il]-2-[rac-(6R)-6-fluoro-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamida.
ARP200101744A 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR AR121167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21

Publications (1)

Publication Number Publication Date
AR121167A1 true AR121167A1 (es) 2022-04-27

Family

ID=67001684

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP200101746A AR119207A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101744A AR121167A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP200101746A AR119207A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Country Status (20)

Country Link
US (2) US20220315591A1 (es)
EP (2) EP3986567B1 (es)
JP (2) JP7530390B2 (es)
KR (1) KR20220024096A (es)
CN (2) CN113993590B (es)
AR (2) AR119207A1 (es)
AU (1) AU2020296933A1 (es)
BR (1) BR112021024810A2 (es)
CA (1) CA3139171A1 (es)
CL (1) CL2021003373A1 (es)
CO (1) CO2021016967A2 (es)
CR (1) CR20210614A (es)
IL (1) IL287806A (es)
MA (1) MA56507A (es)
MX (1) MX2021015889A (es)
PE (1) PE20220807A1 (es)
PH (1) PH12021553018A1 (es)
TW (2) TW202115070A (es)
WO (2) WO2020254547A1 (es)
ZA (1) ZA202108775B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993873B (zh) * 2019-06-21 2024-08-02 豪夫迈·罗氏有限公司 用于治疗癌症的egfr抑制剂
TW202115070A (zh) * 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑
JOP20220107A1 (ar) 2019-11-11 2023-01-30 Dana Farber Cancer Inst Inc مثبطات egfr تفارغية وطرق استخدامها
CR20230218A (es) * 2020-12-01 2023-07-07 Hoffmann La Roche Nuevos derivados de indazol acetileno
CR20250458A (es) 2023-03-30 2025-11-21 Revolution Medicines Inc Composiciones para inducir la hidrólisis de ras gtp y sus usos
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307365B1 (en) 2008-06-25 2013-03-27 Merck Sharp & Dohme Corp. Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
EP3317273B1 (en) * 2015-06-30 2021-12-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
MA53003A (fr) * 2018-06-29 2021-05-05 Hoffmann La Roche Composés
EP3986565B1 (en) 2019-06-21 2023-08-30 F. Hoffmann-La Roche AG New egfr inhibitors
CN113993873B (zh) * 2019-06-21 2024-08-02 豪夫迈·罗氏有限公司 用于治疗癌症的egfr抑制剂
TW202115070A (zh) * 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑

Also Published As

Publication number Publication date
JP7530390B2 (ja) 2024-08-07
CA3139171A1 (en) 2020-12-24
TW202115070A (zh) 2021-04-16
US20220112199A1 (en) 2022-04-14
CO2021016967A2 (es) 2022-01-17
KR20220024096A (ko) 2022-03-03
CR20210614A (es) 2022-02-11
WO2020254547A1 (en) 2020-12-24
CN113993591A (zh) 2022-01-28
CN113993590B (zh) 2024-08-23
CN113993590A (zh) 2022-01-28
WO2020254546A1 (en) 2020-12-24
MA56507A (fr) 2022-04-27
IL287806A (en) 2022-01-01
AU2020296933A1 (en) 2021-12-02
PH12021553018A1 (en) 2023-08-23
EP3986567C0 (en) 2023-08-30
BR112021024810A2 (pt) 2022-01-25
TW202115073A (zh) 2021-04-16
CL2021003373A1 (es) 2022-10-07
JP2022537772A (ja) 2022-08-29
US20220315591A1 (en) 2022-10-06
MX2021015889A (es) 2022-02-03
JP2022537771A (ja) 2022-08-29
EP3986567A1 (en) 2022-04-27
EP3986566C0 (en) 2023-08-30
PE20220807A1 (es) 2022-05-20
JP7561779B2 (ja) 2024-10-04
ZA202108775B (en) 2022-09-28
EP3986567B1 (en) 2023-08-30
AR119207A1 (es) 2021-12-01
EP3986566B1 (en) 2023-08-30
EP3986566A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
AR121167A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
AR119210A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
CL2008003023A1 (es) (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer.
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
PE20221724A1 (es) Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr)
NZ711540A (en) Fused heterocyclic compounds as protein kinase inhibitors
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CL2009000687A1 (es) Compuestos derivados de heterociclos nitrogenados de imidazol, inhibidores de la actividad de cinasa raf; composicion farmaceutica; utiles para el tratamiento del cancer, tal como carcinoma de pulmon, pancreatico, de prostata, tiroides, entre otras.
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
NO20092657L (no) Bicyclic heterocyclic compounds as FGFR inhibitors
PE20081341A1 (es) Inhibidores de la actividad de la akt
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
MX2020006293A (es) Derivados de 5-(2-2,5-difluorofenil)pirrolidin-1-il)-3-(1h-pirazol -1-il)pirazolo[1,5-a]pirimidina y compuestos relacionados como inhibidores de trk cinasa para el tratamiento de cancer.
EA201891157A1 (ru) Способы и промежуточные соединения при получении ингибитора jak
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
NZ597647A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
BRPI0919873A2 (pt) composto de pirazol[1,5-a]pirimidina substituídos como inibidores da quinase trk
NZ591427A (en) P38 map kinase inhibitors
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
NZ599932A (en) Imidazopyridine derivatives as jak inhibitors
RU2009128966A (ru) Новые производные аминопиримидина в качестве ингибиторов plr1
PE20081372A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE 2-[4-(7-ETIL-5H-PIRROLO[2,3-b]PIRAZIN-6-IL)-FENIL]-PROPAN-2-OL COMO INHIBIDOR DE QUINASA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal